Company Filing History:
Years Active: 2023
Title: **Inventor Spotlight: Kelli Jette**
Introduction
Kelli Jette, a prominent inventor based in Somerville, MA, has made significant contributions to the field of pharmaceutical development. With her innovative work particularly focused on cholesterol regulation, Jette's contributions have the potential to impact the treatment of various cardiovascular diseases.
Latest Patents
Kelli Jette holds a notable patent for "Cyclic polypeptides for PCSK9 inhibition." This patent outlines cyclic polypeptide compounds designed to bind specifically to human proprotein convertase subtilisin/kexin type 9 (PCSK9). These compounds are engineered to inhibit the interaction between PCSK9 and the low-density lipoprotein receptor (LDLR). The patented compounds include pharmaceutical compositions capable of reducing LDL cholesterol levels in patients who require such intervention.
Career Highlights
Jette currently works at Ra Pharmaceuticals, Inc., a company dedicated to pioneering advancements in drug development. Her dedication and innovative thinking in this specialized area have paved the way for significant scientific breakthroughs that enhance the efficacy of cholesterol-lowering therapies.
Collaborations
Throughout her career, Kelli Jette has collaborated with distinguished colleagues, including Alonso Ricardo and Nicolas Cedric Boyer. These partnerships emphasize the importance of teamwork in research and the collective effort to achieve groundbreaking advancements in medicine.
Conclusion
Kelli Jette exemplifies the spirit of innovation and dedication in the field of pharmaceutical research. Through her patent on cyclic polypeptides, she contributes to enhancing patient care by developing effective solutions for cholesterol management. Jette's work not only stands as a testament to her skills as an inventor but also demonstrates the impactful role of women in science and technology.